AKTX - Akari Therapeutics, Plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Akari Therapeutics, Plc

75/76 Wimpole Street
London W1G 9RT
United Kingdom
44 20 8004 0270
http://www.akaritx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Dr. Ray PrudoExec. Chairman318.27kN/A1945
Mr. Clive RichardsonCOO, CEO & Director520.84kN/A1965
Dr. Miles NunnChief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

Corporate Governance

Akari Therapeutics, Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.